The Drug Innovation Master’s programme focuses on interdisciplinary research in the field of the innovation and usage of drugs, biologicals (vaccines, monoclonal antibodies, gene therapeutics) and diagnostics. Research teams of several institutes participate in the Drug Innovation Master’s programme. More information on participating organisations. This international Master's programme offers a challenging study programme introducing you to and training you in the fascinating world of drug research. Typical research questions addressed in the field of Drug Innovation include: How do we make new drugs against resistant microorganisms? Which proteins can we target for personalized cancer medicine? Can we differentiate stem cells by means of proteomics? How can we imprint the immune system to become tolerant? What is the connection between gut microbes and brains disease? Can we deliver proteins and gens to diseased cells, by learning from viruses and bacteria? How can we innovate and speed up the regulatory process of weighing benefit and risk? Which biomarkers predict for quality adjusted life years? Despite a better understanding of the underlying mechanisms of disease, the number of newly introduced innovative drugs is steadily decreasing. As drugs have proven to be effective and inexpensive weapons against disease in the 20th century (e.g. antibiotics and psychopharmaceuticals), it is important to reverse this worrying trend using innovative techniques. Graduates with an MSc in Drug Innovation will be eligible for many PhD programmes. They will subsequently be able to contribute to drug innovation within research institutes, any of the growing number of pharmaceutical and biotechnology companies or health care organisations. Drug Innovation Master’s students can opt to facilitate drug research in another way by choosing a Management, Communication & Education or Drug Regulatory Sciences profile. We also offer this degree programme as a part-time course. This, however, does not involve evening or weekend courses.

-